Systems for evaluation of new drugs in the United Kingdom | Zendy

Beard Keith | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Systems for evaluation of new drugs in the United Kingdom

Author(s) -

Beard Keith

Publication year - 2001

Publication title -

pharmacoepidemiology and drug safety

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.023

H-Index - 96

eISSN - 1099-1557

pISSN - 1053-8569

DOI - 10.1002/pds.596

Subject(s) - excellence , medicine , prioritization , nice , health care , healthcare system , health services , service (business) , public administration , economic growth , environmental health , business , political science , marketing , population , law , process management , computer science , economics , programming language

The cost of drugs represents 10% of the National Health Service (NHS) budget in the UK and this fraction is increasing. Because the NHS is centrally funded and because there is a budgetary limit, prioritization in health care is required. The National Institute for Clinical Excellence in England and Wales and the Health Technology Board for Scotland have been established with the aim (among others) of ensuring that the NHS secures maximum health gain from available resources by focusing on treatments with clear evidence of cost effectiveness. Reconciling the interests of those responsible for financing the service with the interests of patients and other concerned parties might prove difficult. Copyright © 2001 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research